On the one hand, the Totality collection kit offers oncologists the flexibility to customize the testing workflow according to the patient’s previous testing and treatment history. “By bringing all the different assays in a single diagnostic kit, Totality drastically improves the physician and patient experience,” states Joseph Cohil, Head of Synergy Oncology. Totality provides industry-leading turnaround time, the lowest possible specimen requirements, and unparalleled convenience for physicians and patients. By bringing all these genomics portfolios in a single collection kit,
The kit also offers a solitary assay for myeloid malignant cancer types. It hence avoids the delay oncologists conventionally face when germline mutations are found in a specimen. Additionally, if germline mutations are identified in a tissue or liquid sample, Totality provides a reflex to hereditary cancer testing assay. Totality empowers oncologists to reflex from one assay to the other if the former fails to detect actionable biomarkers, subsequently preventing delays that occur when an NGS test fails to give an optimum result. Totality thus allows oncologists the flexibility to conduct multiple assays concurrently. Notably, Totality brings together four different assays-Totality Tissue CDx for tissue biopsy, Totality Liquid CDx for liquid biopsy, Totality Hereditary for hereditary cancers, and Totality Myeloid Malignancies for myeloid malignant cancer types. Synergy Oncology leverages datadriven and comprehensive genomic and molecular testing to help physicians make informed decisions through its one-of-a-kind kit. Synergy Oncology is a division of Synergy Laboratories, one of the leading laboratory services providers in the American Southeast. That’s where Synergy Oncology is all set to revolutionize cancer diagnosis with its genomic testing kit- Totality-that brings together solid tumor and circulating tumor testing in a single kit. This delay in turnaround time due to a failed NGS can be life-threatening for a patient as the battle against cancer is indeed a race against time. The liquid biopsy test has to be conducted depending on the doctor’s and patient’s schedules, and the result typically takes at least two to three weeks. As the risks and costs associated with another tumor tissue retrieval are high, the doctor would then consider going for a liquid biopsy, which is a lessinvasive process.
But what if the quantity or quality of the tissue specimen is low? If the sample is insufficient, the test cannot be performed and if the specimen has poor quality, the test results will not be reliable.
The oncologist goes with the current gold standard for cancer diagnosis-tissue biopsy. Let’s say a patient with advanced cancer approaches an oncologist to determine the presence of a cancer mutation. NGS has the potential to facilitate the diagnosis of multiple cancer genes simultaneously, but the lack of a thoroughgoing approach in NGS testing is hindering the quick detection of cancer mutations, adversely affecting cancer care. Consider the case of Next-Generation Sequencing (NGS) genomic testing, for instance, which is now being preferred over individual tests by oncologists.
However, there is still significant room for improvement in its care delivery. Joseph Cohil, Head, Synergy Oncology Precision oncology is swiftly replacing the one-size-fits-all therapies with individualized therapeutic strategies and enhancing the standard of cancer care.
0 kommentar(er)
